权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Improving Functional Outcomes of Veterans with PTSD and Tobacco Dependence

改善患有创伤后应激障碍和烟草依赖的退伍军人的功能结果

基本信息

批准号：
9394730
负责人：
Megan Marie Kelly
金额：
--
依托单位：
EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9394730
关键词：
Abstinence Achievement American Lung Association Area Behavior Therapy Cause of Death Chronic Coping Skills Development Evidence based treatment Freedom General Population Goals Health Impairment Individual Intervention Life Medical Memory Mental Health Modeling Monitor Morbidity - disease rate Nicotine Withdrawal Outcome Participant Physical Exercise Physical Function Post-Traumatic Stress Disorders Process Assessment Quality of life Randomized Randomized Clinical Trials Recruitment Activity Research Site Smoker Smoking Social Functioning Social Network Staging Structure Symptoms Testing Tobacco Tobacco Dependence Tobacco Use Cessation Tobacco use Training Trauma Veterans Withdrawal Symptom Withholding Treatment Work base control trial coping craving functional disability functional outcomes health related quality of life high risk improved improved functioning innovation mindfulness mortality negative affect nicotine patch non-smoker novel primary outcome programs psychosocial public health relevance response retention rate smoking cessation social standard care symptom management therapy development tobacco abstinence treatment adherence treatment effect treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Veterans with PTSD have high rates of smoking (34%-86% vs. 18% in the general population) and have substantial difficulties with quitting tobacco. Only 23% of individuals with PTSD quit smoking compared to 50% of the general population. As a result, Veterans with PTSD are at high risk of developing severe health problems and poor physical functioning. Fifty percent of these long-term smokers will die of a smoking-related cause and on average, will lose 25 years of their life compared to non-smokers. Despite the significant morbidity and mortality associated with smoking, no smoking cessation treatments exist that intensively target PTSD symptoms as an obstacle to quit smoking, although this is a significant barrier to quitting for many Veterans. n addition, no smoking cessation treatments have a large emphasis on improving the functioning of Veterans with PTSD and tobacco dependence, although both PTSD and tobacco use negatively affect functioning across physical, mental health, and social domains. The goal of this SPiRE project is to evaluate Acceptance and Commitment Therapy for Veterans with PTSD and Tobacco Use (ACT-PT), which is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values. This emphasis on substantially improving health-related quality of life and functioning across several areas makes ACT-PT particularly innovative and different from existing treatments. However, research is needed on the relative feasibility, acceptability, and efficacy of ACT-PT compared to standard smoking cessation treatments. The proposed SPiRE (I21) will involve a randomized clinical trial study of 50 Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment 10 individual sessions of ACT-PT (n= 25) versus 10 individual sessions of the American Lung Association's Freedom From Smoking Program [FFS] (n=25) with all participants receiving 12 weeks of the nicotine patch. This study has two primary aims: 1) evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.